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Background: The purpose of this study was to develop a mucoadhesive coacervate 
  microparticulate system to deliver viable Lactobacillus rhamnosus cells into the gut for an 
extended period of time while maintaining high numbers of viable cells within the formulation 
throughout its shelf-life and during gastrointestinal transit.
Methods: Core coacervate mucoadhesive microparticles of L. rhamnosus were developed 
using several grades of hypromellose and were subsequently enteric-coated with hypromel-
lose phthalate. Microparticles were evaluated for percent yield, entrapment efficiency, surface 
morphology, particle size, size distribution, zeta potential, flow properties, in vitro swelling, 
mucoadhesion properties, in vitro release profile and release kinetics, in vivo probiotic activ-
ity, and stability. The values for the kinetic constant and release exponent of model-dependent 
approaches, the difference factor, similarity factor, and Rescigno indices of model-independent 
approaches were determined for analyzing in vitro dissolution profiles.
Results: Experimental microparticles of formulation batches were of spherical shape with 
percent yields of 41.24%–58.18%, entrapment efficiency 45.18%–64.16%, mean particle 
size 33.10–49.62 µm, and zeta potential around −11.5 mV , confirming adequate stability of 
L.   rhamnosus at room temperature. The in vitro L. rhamnosus release profile follows zero-
order   kinetics and depends on the grade of hypromellose and the L. rhamnosus to hypromel-
lose ratio.
Conclusion: Microparticles delivered L. rhamnosus in simulated intestinal conditions for an 
extended period, following zero-order kinetics, and exhibited appreciable mucoadhesion in 
simulated intestinal conditions.
Keywords: Lactobacillus rhamnosus, mucoadhesive, microparticles, extended-release, 
intestine
Introduction
Intake of viable Lactobacillus rhamnosus (LR) cells, at around 107 cfu,1,2 aids in the 
prevention of intestinal tract illnesses,3 suppresses bacterial infection in renal patients,4 
safeguards the urogenital tract by excreting biosurfactants,5 stimulates antibody 
  production, aids the immune system, assists the phagocytic process, helps the body to 
combat dangerous invasive bacteria, controls food-associated allergic inflammation,6 
shortens the duration of diarrhea associated with rotavirus infection,7 and reduces use 
of antibiotics to treat Helicobacter pylori infection.8
Reported therapeutic benefits are associated with the ability of LR to secret 
coagulin, a bacteriocin, which is active against a broad spectrum of enteric 
microbes.1 LR is well tolerated with very rare side effects, and its regular intake can International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1700
Alli
be effective in   supplementing and maintaining   digestive 
tract health. Processing conditions during formulation 
and noncompliance with storage requirements during 
shipment and storage result in loss of cell viability in the 
dosage formulation. Acidic conditions in the stomach, 
various hydrolytic enzymes, and bile salts in the gastroin-
testinal tract also adversely affect the viability of LR after 
ingestion.9–14
Nowadays, microparticulate systems have been 
exploited, not only to reduce loss of cell viability during 
storage and transport, but also to improve and maintain 
viable cells arriving in the intestine.9–11 Decreased per-
formance of microparticles is attributable to their short 
gastric retention time, a physiological limitation which 
can be improved by coupling mucoadhesion properties 
to the microparticles through developing mucoadhesive 
microparticles which will in turn simultaneously improve 
gastric retention time and bioavailability.15–17 Hypromellose 
and hypromellose phthalate are safe for human consump-
tion, and because of the good mucoadhesive and release 
rate-controlling properties of hypromellose, it is preferred 
in mucoadhesive formulations.16–19 These observations 
indicate a strong need to develop a dosage form that will 
deliver LR into the gut with improved gastric retention 
time and adequate stability during storage and gastrointes-
tinal transit, which can be achieved with extended-release 
mucoadhesive microparticles.
Materials and methods
Materials
Freeze-dried LR R0011-150 powder was donated by Cipla 
Limited (Mumbai, India). Hypromellose phthalate (HP-50) 
was donated by Glenmark Pharmaceuticals Limited (Nasik, 
India). Different grades of hypromellose, ie, Methocel E5 
Premium LV (E5), Methocel E50 Premium LV (E50), and 
Methocel E10 M Premium CR (E10 M), were donated by 
Indoco Remedies Limited (Mumbai, India). DeMann Rogosa 
Sharpe agar media and other analytical grade laboratory 
chemicals were purchased from HiMedia Laboratories Limited 
(Mumbai, India).
In-house LR specification compliance test
A number of cell count tests (bacteriological, total aerobic 
bacteria, coliforms, enterobacteriaceae, other Gram-negative 
bacteria, yeast, molds), and tests to ensure the absence of 
contaminants (Escherichia coli, Staphylococcus aureus, 
and Salmonella), were performed as a compliance to the 
specifications of the certificate of analysis.
Preparation of mucoadhesive 
microparticles
Core mucoadhesive microparticles of LR were prepared 
aseptically with hypromellose employing coacervation 
and phase separation technique.16,20 Hypromellose 5 g was 
dissolved in 200 mL of cold deionized water (4°C ± 2°C). 
Polysorbate-80 2 g was dissolved in this solution under stir-
ring, followed by aseptic filtration using a 0.45 µm PVDF 
filter membrane (Millipore Corporation, Bedford, MA). 
A calculated quantity of LR was dispersed in the above solu-
tion, sonicated at 20 kHz for 1 minute, and the temperature was 
raised gradually up to 30°C ± 2°C with stirring at 500 ± 25 rpm 
for 30 minutes. Acetone 50 mL was added dropwise under 
stirring and stirred for a further 10 minutes. Microparticles 
were collected by aseptic filtration of the dispersion with 
a 10 µm nylon filter (Millipore Corporation), followed 
by washing three times with sterile water for injection 
(30°C ± 2°C) and kept in a desiccator for 24 hours. All 
formulation batches having the composition described in 
Table 1 were prepared in triplicate. Aseptic processing was 
carried out on the bench using a horizontal laminar flow 
clean air work station (1500048-24-24, Klenzaids Bioclean 
Devices Ltd, Mumbai, India).16,20
coating of microparticles
HP-50 solution 200 mL (10% w/w) was prepared with 
phosphate buffer21 at pH 6.8, and polyethylene glycol 200 
4 g and polysorbate-80 2 g was dissolved in it. The solu-
tion was filtered aseptically using a 0.45 µm PVDF filter 
membrane followed by dispersing tare core microparticles 
in it under stirring at 300 ± 25 rpm, and then 40 mL of 
propan-2-ol was added dropwise. Stirring was continued 
for 30 minutes, then the coated microparticles were sepa-
rated by aseptic filtration, washed three times with sterile 
water for injection (30°C ± 2°C), and kept in a desiccator 
for 24 hours, followed by determination of the final weight, 
aseptically packed in glass vials, and stored in a refrigera-
tor for further use.
coating stage percent weight gain
From the tare weight (WI) of the dried core microparticles 
that had been subjected to coating and the tare weight (WF) 
of the dried coated microparticles, the coating stage percent 
weight gain value was determined using equation 1.
 
Coating stage percent weight gain (% w/w)
=
WW
W
F I
I
− × 100
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Percent yield study
Calculation for percent yield values (w/w) of all batches were 
done using equation 2.
 
Percent yield   
W  (weight of coated 
microparticles recove
1
=
r red)
W  [Weight (drug (viable cell 
 nonviable cell) + pol
2
+ y ymer)]
   100 ×
(2)
Measurement of viable cell number
Measurement of viable cells in sample was done using the 
following methods.22
Direct microscopic count using dye exclusion test
A thoroughly mixed cell suspension (2–5 × 105 cells/mL) was 
aseptically prepared to 1 mL with sterile phosphate buffer 
pH 6.8. Cell suspension 200 µL was mixed thoroughly with 
300 µL of sterile phosphate buffer pH 6.8 and 500 µL of 0.4% 
Trypan blue solution in a 1.5 mL microfuge tube (creating a 
dilution factor of 5), and kept aside for five minutes. With a 
coverslip in place, a small volume of the Trypan blue cell sus-
pension was transferred into the chamber of a hemocytometer 
using a Pasteur pipette and the chamber was allowed to fill 
Table 1 Formulation formulae and values of evaluation parameters of all formulation batches
Formulation code/ 
parameter
F1 F2 F3 F4 F5 F6
grade of Methocel Premium used e5–LV e5–LV e15–LV e15–LV e10M–cr e10M–cr
Lactobacillus rhamnosus to polymer ratio 1:1 1:2 1:1 1:2 1:1 1:2
Percent yield (w/w)a 58.18 ± 1.98 49.21 ± 1.89 54.91 ± 1.86 45.46 ± 1.63 49.32 ± 1.83 41.24 ± 1.76
Entrapment efficiency (% cfu/g)a 64.16 ± 1.53 57.25 ± 1.81 58.42 ± 1.96 52.62 ± 1.79 51.84 ± 1.86 45.18 ± 1.73
Mean particle size (µm)a 33.10 ± 1.32 35.90 ± 1.53 36.45 ± 1.58 44.23 ± 1.96 46.32 ± 2.02 49.62 ± 1.87
Zeta potential (mV)a
  Uncoated microparticles −19.2 ± 0.3 −19.1 ± 0.5 −19.3 ± 0.7 −19.4 ± 0.4 −18.9 ± 0.9 −19.3 ± 0.8
  coated microparticles −11.6 ± 0.3 −11.6 ± 0.8 −11.4 ± 0.9 −11.3 ± 0.6 −11.8 ± 0.6 −11.2 ± 0.7
Percent swellinga   1.38 ± 0.049   1.24 ± 0.046   1.13 ± 0.039   1.03 ± 0.043   0.88 ± 0.038   0.82 ± 0.031
Percent adhesive strengtha 73.36 ± 1.32 68.86 ± 1.53 62.64 ± 1.71 55.51 ± 1.46 48.71 ± 1.34 42.61 ± 1.42
Percent mucoadhesiona 75.92 ± 1.57 69.31 ± 1.65 61.35 ± 1.43 54.79 ± 1.54 49.52 ± 1.24 44.43 ± 1.33
Zero-order kinetic constants
  Regression coefficient (r2) 0.9834 0.9947 0.9892 0.9916 0.9932 0.9875
  Proportionality constant (K0) 6.3842 5.1419 3.7874 4.3137 3.3727 2.6908
First-order kinetic constants
  Regression coefficient (r2) 0.5863 0.7402 0.6524 0.8446 0.8178 0.7365
  release rate constant (K) 0.0413 0.0460 0.0411 0.0485 0.0449 0.0382
hixson-crowell model kinetic constants
  Regression coefficient (r2) 0.8993 0.9912 0.9928 0.9903 0.9971 0.9914
  surface-volume relation constant (Ks) 0.3289 0.1129 0.1008 0.0849 0.0627 0.0488
Weibull model kinetic constants
  scale parameter (α) 69.324 47.422 48.651 34.893 29.445 26.361
  shape parameter (β) 1.8397 1.2381 1.5977 1.0823 1.1826 1.5970
  Location parameter (Td) 10.015 22.575 11.375 26.637 17.467 7.7580
  Regression coefficient (r2) 0.9428 0.9399 0.9402 0.9310 0.9449 0.9670
Note: aData presented as mean value ± standard error, n = 3.
up by capillary action to avoid overfilling or   underfilling. All 
the cells (nonviable cells stain blue and viable cells remain 
opaque) in the 1 mm center square and the four corner squares 
were counted under a microscope. The number of viable cells 
per unit of sample (g or mL) was calculated using equation 3. 
This is a simple and rapid method that provides an approxi-
mate result, and was performed in triplicate.
Viable cells =   average viable cells count per square  
× dilution factor × 104  (3)
Viable plate counts
One gram of sample, alternately one mL of sample solution, 
containing LR was transferred aseptically into a presterilized 
10 mL volumetric flask containing 5 mL of sterile saline TS, 
sonicated at 20 kHz for one minute, and diluted to 10 mL 
with sterile saline TS. One mL of this suspension was diluted 
to 10 mL in an autoclaved test tube (25 mm × 150 mm size) 
with sterile saline TS and mixed thoroughly. Serial dilution 
was continued until a suitable dilution was achieved (approxi-
mately 100 cell/mL). The final dilution tube was allowed to 
stand in a water bath at 70°C for 30 minutes and was then 
cooled immediately to about 45°C. Saline TS,21 simulated International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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gastric fluid TS, 21 and simulated intestinal fluid TS21 contain 
inorganic salts but no carbon source, thus LR cells will not 
proliferate in this media, and remain in a state of stasis until 
plated on media containing a carbon source.22
DeMann Rogosa Sharpe agar medium was liquefied and 
cooled to 45°C on a water bath. One mL of sample from the 
heat-treated final dilution tube was transferred into sterile 
Petri dishes (six per sample), and 15 mL of molten medium 
was poured, mixed thoroughly, and then incubated in an 
inverted position at 40°C for 48 hours after solidification.
Six plates were counted and the average count per plate 
was calculated. The number of cfu per unit (mL or g) of 
sample was calculated using equation 4.
Number of cfu   
Average number of colonies 
counted per pla
=
t te
Dilution factor
    100 ×
(4)
Entrapment efficiency
In an aseptic manner, 500 mg of accurately weighed coated 
microparticles were kept with 25 mL of sterile simulated 
intestinal fluid in a hermetically sealed sterile glass vial at 
4°C ± 2°C for 24 hours. The dispersion was subjected to a 
viable plate count (ie, a viable spore count value in cfu/g) and 
entrapment efficiency was calculated using equation 5.16
Percent entrapment 
efficiency   
Practical viable spore 
cou
=
n nt value
Theoretical viable spore 
count value
   100 ×
  (5)
Morphology
The coated microparticles were mounted on aluminum stubs 
using double-sided adhesive tape. The stubs were then vacuum-
coated with a thin layer of gold and examined with a scanning 
electron microscope (JSM 5610 LV , Jeol, Tokyo, Japan).23–28
Particle size, size distribution, and zeta 
potential
The core and coated microparticles were dispersed in 
deionized water (pH 6.8) and sonicated at 20 kHz for 
three minutes to get a homogenous dispersion (0.5% w/v). 
The dispersions were put into a small-volume disposable 
zeta cell and subjected to particle size study using photon 
correlation spectroscopy with an inbuilt Zetasizer (Nano 
ZS, Malvern Instruments, Worcestershire, UK) at 633 nm 
and 25°C ± 0.1°C. The electrophoretic mobility measured 
(in mm/sec) was converted to the zeta potential.16,25–30
Flow properties
The flow properties of the coated microparticles were deter-
mined from the result of the study parameters, ie, angle of 
repose, Carr’s index, and the Hausner ratio.16,21
In vitro swelling
An in vitro swelling test of the coated microparticles was 
conducted in simulated intestinal fluid. The size of the 
dried microparticles and those after incubation in simulated 
intestinal fluid for 5 hours were measured using a calibrated 
optical microscope (CX RIII, Labomed, Ambala, India). 
Percent swelling value was determined from the diameter 
of the microparticles at time t (DT) and initial time t= 0 (D0) 
using equation 6.16
  Percent swelling = [DT
 − D0]/D0 × 100  (6)
Mucoadhesion
Following institutional animal ethical committee guide-
lines, the mucoadhesion affinity of the coated micropar-
ticles for intestinal mucosa was assessed by the following 
methods.
ex vivo mucoadhesive strength
A suspension of coated microparticles in simulated intestinal 
fluid was prepared, and the number of microparticles per mL 
(No) was determined by optical microscopy. One mL of this 
suspension was fed to overnight-fasted albino rats of either 
gender (in groups of three) which were then sacrificed at 
hours 0, 4, 8, and 12 to isolate their stomach and intestinal 
regions. The number of microparticles adhering to the 
stomach and the intestinal regions (NS) was counted after 
the regions were cut open longitudinally. Percent adhesive 
strength value as a measure of ex vivo mucoadhesive strength 
test was calculated using equation 7.16
  Percent adhesive strength = [NS/N0] × 100  (7)
In vitro washoff test
A strip of goat intestinal mucosa was mounted on a glass 
slide, on which a dispersion of accurately weighed micropar-
ticles (W a) in simulated intestinal fluid was uniformly spread 
and incubated in a desiccator at 90% relative humidity for 
15 minutes. The slide was then placed in a cell at an angle 
of 45°. Simulated intestinal fluid of 37°C ± 0.5°C was cir-
culated at a rate of 1 mL/min to the cell over microparticles 
adhering to the intestinal mucosa. The weight of washed 
out microparticles (Wf) in the washings was determined by 
separation through centrifugation followed by drying at 50°C. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The percent mucoadhesion value as a measure of the in vitro 
washoff test was calculated using equation 8.31
  Percent mucoadhesion = [(W a − Wf)/Wa] × 100  (8)
In vitro release
In vitro release studies of the coated microparticles were 
done using a USP basket apparatus (TDT-06T, Electrolab, 
  Mumbai, India) at 37°C ± 0.5°C and 100 rpm containing 
900 mL of sterile dissolution medium, ie, simulated gas-
tric fluid and simulated intestinal fluid with about 1 g of 
accurately weighed microparticles contained in the basket 
(wrapped with 100 mesh nylon cloth) of dissolution appa-
ratus. At predetermined time points, 5 mL of dissolution 
medium was withdrawn for up to 14 hours, with immediate 
replacement of fresh dissolution medium, subjected to viable 
cell number determination, and the result was expressed as 
the percentage of viable LR cells released with respect to the 
practical viable spore count value.16
In vitro release kinetics, statistical 
evaluation, and data fitting
A mean value of three determinations at each time point 
was used to fit an in vitro viable cell release profile of all 
formulation batches to different kinetic models so as to find 
their release exponents. The mean value of 12 determinations 
was used to estimate the difference factor (f1), the similarity 
factor (f2), and the two indices of Rescigno (ξ1 and ξ2).16,32 
Statistical analysis of percent released data and other data were 
performed using one-way analysis of variance at a significance 
level of 5% (P , 0.05). In vitro release kinetic studies, statisti-
cal evaluation, data fitting, nonlinear least square curve fitting, 
simulation, and plotting were performed using Excel software 
(version 2007, Microsoft Software Inc, Redmond, WA) for 
determining the parameters of each equation.
In vivo probiotic activity
The in vivo probiotic activity of the coated microparticles was 
evaluated using a mouse enterococci stool colonization method, 
following institutional animal ethical committee guidelines.16 
One milliliter of coated microparticle dispersion (102 cfu/mL) in 
simulated intestinal fluid was fed to albino mice in groups of six. 
Stools were collected at 6-hourly intervals for up to 48 hours 
and subjected to an enterococci colonization density study.
Accelerated stability
Following an International Conference on Harmonization 
guidelines, coated microparticles from all formulation 
batches were stored under a range of temperature and 
  humidity conditions (30°C ± 2°C/65% ± 5% relative humidity 
and 40°C ± 2°C/75% ± 5% relative humidity) in a stability 
analysis chamber (Darwin Chambers Company, St Louis, 
MO) and in a refrigerator (2°C–8°C) for an accelerated 
stability study of up to six months.16,32,33
Results and discussion
The coacervation and phase separation technique described 
here is a simple, rapid, two-step method, which appears 
to be suitable for the preparation of coacervate extended-
release mucoadhesive microparticles loaded with LR cells. 
It eliminates exposure of LR cells to high temperatures, 
organic solvents, and mechanical stress, while maintaining 
their viability during processing. Temperatures above 20°C 
and nonaqueous solvents adversely affect and decrease 
the viability of LR, and this is the reason for commencing 
developmental processes below 20°C in aqueous medium. 
Hypromellose is soluble in cold water, with solubility in water 
decreasing with increasing temperature, and it is insoluble 
in organic solvents like chloroform, dichloromethane, ether, 
and acetone.19 Hypromellose has excellent rate-controlling 
and mucoadhesion properties.16,17,19 Hypromellose phthalate 
is soluble in aqueous alkali and insoluble in water and 
propan-2-ol.19 Hypromellose was selected as a mucoadhesive 
polymer and hypromellose phthalate as a coating polymer 
because of their aforementioned properties, and both 
are considered to be safe for human consumption.16–19 
Polysorbate-80 was incorporated in the formulation as a 
dispersing agent for homogeneous dispersion of LR cells, and 
polyethylene glycol 200 was incorporated into the coating 
solution as a plasticizer to impart plasticity to the coat and 
to prevent it from splitting and cracking.
LR cells used complied with certificate of analysis 
specifications, when tested in accordance with the method of 
analysis provided by the manufacturer. Coating stage percent 
weight gain values of the formulation batches were in the 
range of 10.1%–13.2% w/w.
The percent yield value of the formulation batches 
ranged from 41.24% to 58.18% w/w, which varied according 
to the grade of hypromellose used, following the order 
E5 . E50 . E10 M, and an increase in the LR to hypromellose 
ratio decreased the value, and the highest value was observed 
for the formulation containing E5 (Table 1). A similar trend 
was also noticed for the entrapment efficiency values that lie 
between 45.18% and 64.16% cfu/g.
Scanning electron micrographs (Figure 1) of formulations 
F1, F3, and F5 demonstrate the surface morphology and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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  particle size of the coated microparticles. The microparticles 
of all formulation batches were spherical in shape with a 
smooth surface, with the exception of microparticles belong-
ing to formulation F5, the surface morphology of which was 
found to be coarser and shriveled. A coarser and shriveled 
surface texture in turn will improve adhesion by having 
stronger mechanical interactions.17
The mean particle size values of all formulation batches 
were in the range of 33.10–49.62 µm (Table 1), which 
increases with an increase in polymer concentration, while 
that the grade of hypromellose varied according to mean 
particle size value in the order of E10 . E50 . E5 M, with 
the highest value for microparticles prepared with E10 M 
(Table 1 and   Figure 2). A nearly equal zeta potential of 
around −19.2 mV was observed for uncoated microparticles 
of all formulation batches, while coated microparticles had 
a nearly equal zeta potential at around −11.5 mV . This value 
is lower than that of the coated microparticles, indicating 
the presence of hypromellose phthalate on the surface of 
the microparticles. The zeta potential report for the uncoated 
microparticles from formulation batch F1 is shown in Fig-
ure 3. The flow properties of the formulation batches lie 
within the passable and very poor ranges.
The percent swelling value of the formulation batches 
was 0.82%–1.38%, and decreases with increasing LR to 
hypromellose ratio. A variation in the grade of hypromellose 
also decreased the value in the order of E5 . E50 . E10 M, 
with the highest value for the microparticles prepared with 
E5 (Table 1).
The percent adhesive strength of all formulation batches 
was 42.61%–73.36%, which decreases with an increase 
in the LR to hypromellose ratio (Table 1). A difference in 
the grade of hypromellose varied the value in the order of 
E5 . E50 . E10 M, with the highest value seen for E5. 
A similar trend was also noticed with the percent mucoadhe-
sion value, which ranged between 44.43% and 75.92% for all 
formulation batches. These results indicate that the mucoad-
hesion properties of the microparticles varied according to 
the grade of hypromellose and the LR to hypromellose ratio, 
and that microparticles from formulation batch F1 had the 
highest mucoadhesion affinity with the intestinal mucosa, so 
may exhibit high gastric retention time in comparison with 
the other batches.
The in vitro swelling test result, ex vivo mucoadhesive 
strength determination, and in vitro washoff test result, as 
a measure of the mucoadhesion affinity of the micropar-
ticles reveals that the mechanism of mucoadhesion initially 
  follows the adsorption theory34,35 and subsequently the dif-
fusion theory.35
A
B
C
Figure  1  scanning  electron  microscopy  photographs  of  microparticles  from 
formulation batches (A) F1, (B) F3, and (C) F5.
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The amount of viable LR cells released from the micropar-
ticle system in simulated gastric fluid was negligible, but 
viable LR cell release was almost regulated and extended in 
simulated intestinal fluid (Figure 4), indicating that enteric 
coating of microparticles competently protects cell viability 
at acidic pH, prevents cell release at gastric pH, and releases 
viable LR cells at intestinal pH.
The results of the in vitro swelling test, ex vivo mucoad-
hesive strength determination test, in vitro washoff test, and 
in vitro release profile study demonstrates that, in the intestine 
(pH . 5.0), the coating of the microparticle is dissolved, 
thereby releasing core microparticles. The   liberated core 
microparticles swell in the intestine, resulting in intimate con-
tact between the microparticles and the mucous membrane. 
The mucoadhesive chains then penetrate into the crevices of 
the tissue surface and intermingle with ions in the mucus, 
with formation of hydrogen bonds between the carboxylic 
groups of the polymer chains (hypromellose) and mucin 
molecules, leading to adhesion of the microparticles to the 
mucous membrane lining the intestinal wall.36–38
The kinetic constant and release exponent values of model-
dependent approaches (Table 1) show that the mechanism of 
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Figure 3 Zeta potential report of uncoated microparticles from formulation batch F1.
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Figure 4 Comparative in vitro release profile of viable Lactobacillus rhamnosus cells from coated microparticles of all formulation batches in simulated intestinal fluid TS, 
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Table 2 Values of the dissimilarity factor (f1), the similarity factor (f2) and the two indices of rescigno (ξ1 and ξ2)
Model-independent  
factors
Formulation pair
F1 vs F2 F1 vs F3 F1 vs F5 F2 vs F4 F2 vs F6 F3 vs F4 F5 vs F6 F4 vs F6
ξ1 0.102 0.137 0.328 0.133 0.299 0.098 0.070 0.173
ξ2 0.290 0.248 0.407 0.245 0.334 0.259 0.240 0.335
f1 33.00 30.78 58.00 24.64 43.00 27.00 17.00 29.84
f2 36.00 36.78 24.00 50.14 36.00 48.00 68.00 48.99
viable LR cell release from coated   microparticles follows a zero-
order kinetics model, because the plot of cumulative percent 
viable cell release versus time was found to be linear, with the 
highest regression coefficient (r2) value in comparison with those 
of the other models. For all formulation batches, the zero-order 
kinetics model r2 value ranged between 0.9834 and 0.9947. 
Study of shape parameter values for the Weibull model (Table 1) 
reveal that the curve is sigmoid or S-shaped, with upward cur-
vature, followed by a turning point as β exceeded 1.16,32 Study 
of the location parameter (Td) for the Weibull model (Table 1) 
characterizes the time interval necessary to dissolve or release 
63.2% of the drug present in the delivery system16,32 and shows 
that the Td of the formulation batches ranges from 7.7580 to 
26.637 hours and the r2 value from 0.9310 to 0.9670.
Model-independent release exponent values are listed 
in Table 2, and show that for all formulation pairs, ie, the 
intrapolymer and interpolymer batches, the ξ1 values lie 
between 0.070 and 0.328, the ξ2 values lie between 0.240 and 
0.407, the f1 value lies between 17.00 and 58.00, and the f2 
value lies between 24.00 and 68.00, indicating dissimilarity 
in product performance of the formulation batches.16,32
A plot of the in vitro viable LR cell release profile fol-
lowing a zero-order kinetics model for all formulation 
batches in simulated intestinal fluid is shown in Figure 4, 
and demonstrates that the rate of viable LR cell release from 
the microparticles decreased significantly with an increase 
in the LR to polymer ratio, while variation in the grade of 
hypromellose influenced the release rate from the micropar-
ticles, following the order of E10 . E50 . E5 M.
The in vivo probiotic activity evaluation result shows 
that oral administration of the extended-release mucoadhe-
sive microparticles of LR from all the formulation batches 
resulted in statistically significant reductions in the density 
of enterococci colonization in the stool of albino mice up to 
24 hours to 36 hours.
The stability study result shows adequate stabil-
ity of the microparticles under storage conditions of 
30°C ± 2°C/65% ± 5% relative humidity, with no change in 
color and texture or statistically significant decrease in viable 
LR cell content with respect to the viable spore count, and also 
confirms that the LR cells were compatible with the excipients 
used in the   formulation. A statistically significant decrease in 
viable LR cell content was observed with respect to practical 
viable spore counts at 40°C ± 2°C/75 ± 5% relative humidity, 
indicating product instability under these storage conditions.
Extended-release mucoadhesive microparticles from 
formulation batch F1 was found to be superior to the other 
prototype formulations because it exhibited the highest values 
of percent yield, entrapment efficiency, and mucoadhesion 
affinity, having the ability to protect the viability of LR cells 
during storage and gastrointestinal transit, and releasing 
viable LR cells in the gut for an extended period of time, as 
shown via zero-order kinetics.
Conclusion
These experimental results suggest that this extended-release 
microparticulate system loaded with LR cells could be prepared 
by a conventional coacervation and phase separation technique. 
It has the potential to deliver viable LR cells to the gut for an 
extended period of time, while maintaining the viability of 
LR cells during storage and gastrointestinal transit, and could 
be viewed as an alternative to conventional dosage forms. 
  However, extensive in vivo studies will be required to establish 
the use of a coacervate extended-release microparticulate sys-
tem as an alternative to the conventional dosage form of LR.
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